MULTIHANCE

LOE Approaching

gadobenate dimeglumine

NDAINTRAVENOUSINJECTABLE
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13

Mechanism of Action

and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity…

Clinical Trials (5)

NCT03147989N/ACompleted

Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients

Started May 2017
352 enrolled
Central Nervous System DiseasesCentral Nervous System Neoplasms
NCT02992847N/AUnknown

Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)

Started Jan 2017
160 enrolled
Multiple Sclerosis
NCT03108378N/ACompleted

Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control

Started Oct 2014
28 enrolled
Gadolinium Retention
NCT02070380Phase 4Completed

Crossover Comparison of MultiHance and Dotarem

Started Feb 2014
179 enrolled
Brain Disease
NCT00907530Phase 4Completed

Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain

Started Sep 2009
121 enrolled
Brain Lesions